Bayer In FDA's Bad Books Over Facility Failures
Not for the first time this decade, the German major has been warned by the US FDA about its manufacturing processes and sorting out the problems could affect supplies of some big-selling products such as the blood pressure treatment Adalat and the erectile dysfunction drug Levitra.
You may also be interested in...
Xarelto and Eylea are continuing to sell well but the German major faces another heap of litigation in the US over Monsanto's weedkillers which is alarming shareholders.
Litigation woes at Monsanto are casting a shadow over Bayer but despite the news of some discontinued projects, the German major sees pharma as an integral component and will keep investing in its pipeline.
Moving up the manufacturing compliance curve is still a work in progress for several Indian firms, but there appear to be some early signs that US FDA inspection outcomes, in general, may have improved.